Congress responds to the IOM drug safety report--in full. [electronic resource]
- JAMA Nov 2007
- 2185-7 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural
1538-3598
10.1001/jama.298.18.2185 doi
Clinical Trials as Topic--legislation & jurisprudence Conflict of Interest Databases, Factual Drug Approval--legislation & jurisprudence Drug-Related Side Effects and Adverse Reactions National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division Politics Product Surveillance, Postmarketing United States United States Food and Drug Administration